Role of the Apolipoprotein BApolipoprotein A-I Ratio in Cardiovascular Risk Assessment: A CaseControl Analysis in EPIC-Norfolk

No abstract is available for this paper.

• Publication year

  2007

• Venue

  Annals of Internal Medicine

• Publication date

  2007-05-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.7326/0003-4819-146-9-200705010-00007PMID 17470832
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• An Introduction to the Bootstrap

  2007cited by this paper
• Apo B versus cholesterol in estimating cardiovascular risk and in guiding therapy: report of the thirty‐person/ten‐country panel

  2006cited by this paper
• ATP-binding cassette transporter AI and its role in HDL formation

  2005cited by this paper
• Non-HDL cholesterol and apolipoprotein B predict cardiovascular disease events among men with type 2 diabetes.

  2004cited by this paper
• Macrophage migration inhibitory factor and the risk of myocardial infarction or death due to coronary artery disease in adults without prior myocardial infarction or stroke: the EPIC-Norfolk Prospective Population study.

  2004cited by this paper
• Limitations of the odds ratio in gauging the performance of a diagnostic, prognostic, or screening marker.

  2004cited by this paper
• Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study.

  2004cited by this paper
• Apolipoprotein B and apolipoprotein A‐I: risk indicators of coronary heart disease and targets for lipid‐modifying therapy

  2004cited by this paper
• C-Reactive Protein, the Metabolic Syndrome, and Prediction of Cardiovascular Events in the Framingham Offspring Study

  2004cited by this paper
• Apolipoprotein B determines risk for recurrent coronary events in postinfarction patients with metabolic syndrome.

  2004cited by this paper
• Plasma Levels of Cholesteryl Ester Transfer Protein and the Risk of Future Coronary Artery Disease in Apparently Healthy Men and Women: The Prospective EPIC (European Prospective Investigation into Cancer and nutrition)–Norfolk Population Study

  2004cited by this paper
• IL-8 Plasma Concentrations and the Risk of Future Coronary Artery Disease in Apparently Healthy Men and Women: The EPIC-Norfolk Prospective Population Study

  2004cited by this paper
• The Statistical Evaluation of Medical Tests for Classification and Prediction

  2003cited by this paper
• Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report.

  2002cited by this paper
• Value of HDL Cholesterol, Apolipoprotein A-I, Lipoprotein A-I, and Lipoprotein A-I/A-II in Prediction of Coronary Heart Disease: The PRIME Study

  2002cited by this paper
• Coronary Heart Disease Prediction From Lipoprotein Cholesterol Levels, Triglycerides, Lipoprotein(a), Apolipoproteins A-I and B, and HDL Density Subfractions: The Atherosclerosis Risk in Communities (ARIC) Study

  2001cited by this paper
• Comparison of Various Electrophoretic Characteristics of LDL Particles and Their Relationship to the Risk of Ischemic Heart Disease

  2001cited by this paper
• High apolipoprotein B, low apolipoprotein A-I, and improvement in the prediction of fatal myocardial infarction (AMORIS study): a prospective study.

  2001influential reference
• Relation between baseline and on-treatment lipid parameters and first acute major coronary events in the Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TexCAPS).

  2000cited by this paper
• Apolipoprotein Concentrations During Treatment and Recurrent Coronary Artery Disease Events

  2000cited by this paper
• Coronary and cardiovascular risk estimation for primary prevention:validation of a new Sheffield table in the 1995 Scottish health survey population

  2000cited by this paper
• Normal high density lipoprotein inhibits three steps in the formation of mildly oxidized low density lipoprotein: step 1.

  2000cited by this paper
• Apolipoproteins A–I, A–II and B, lipoprotein(a) and the risk of ischaemic heart disease: the Caerphilly Study

  2000cited by this paper
• Normal high density lipoprotein inhibits three steps in the formation of mildly oxidized low density lipoprotein: steps 2 and 3.

  2000cited by this paper
• Apolipoprotein(B) identifies dyslipidemic phenotypes associated with cardiovascular risk in normocholesterolemic type 2 diabetic patients.

  1999cited by this paper
• EPIC-Norfolk: study design and characteristics of the cohort. European Prospective Investigation of Cancer.

  1999cited by this paper
• Prediction of coronary heart disease using risk factor categories.

  1998cited by this paper
• Smoking and risk of myocardial infarction in women and men: longitudinal population study

  1998cited by this paper
• Activation of the complement system during and after cardiopulmonary bypass surgery: postsurgery activation involves C-reactive protein and is associated with postoperative arrhythmia.

  1997cited by this paper
• Small, dense low-density lipoprotein particles as a predictor of the risk of ischemic heart disease in men. Prospective results from the Québec Cardiovascular Study.

  1997cited by this paper
• Smoking, serum lipids, blood pressure, and sex differences in myocardial infarction. A 12-year follow-up of the Finnmark Study.

  1996cited by this paper
• International Federation of Clinical Chemistry standardization project for measurements of apolipoproteins A-I and B. IV. Comparability of apolipoprotein B values by use of International Reference Material.

  1994cited by this paper
• Lipoprotein Lp(a) as predictor of myocardial infarction in comparison to fibrinogen, LDL cholesterol and other risk factors: results from the prospective Göttingen Risk Incidence and Prevalence Study (GRIPS)

  1994cited by this paper
• Apolipoproteins and ischaemic heart disease: implications for screening.

  1994cited by this paper
• International Federation of Clinical Chemistry standardization project for measurements of apolipoproteins A-I and B. III. Comparability of apolipoprotein A-I values by use of international reference material.

  1993cited by this paper
• Lipids and risk of coronary heart disease. The Framingham Study.

  1992cited by this paper
• Predictive value of apolipoproteins in a prospective survey of coronary artery disease in men.

  1992cited by this paper
• International Federation of Clinical Chemistry standardization project for measurements of apolipoproteins A-I and B. II. Evaluation and selection of candidate reference materials.

  1992cited by this paper
• A prospective study of cholesterol, apolipoproteins, and the risk of myocardial infarction.

  1991cited by this paper
• Usefulness of the total cholesterol to high-density lipoprotein cholesterol ratio in predicting angiographic coronary artery disease in women.

  1991cited by this paper
• Serum fatty acids, apolipoproteins, selenium and vitamin antioxidants and the risk of death from coronary artery disease.

  1985cited by this paper
• Comparison of receiver operating curves derived from the same population: a bootstrapping approach.

  1985cited by this paper
• The analysis of case-control studies

  1980cited by this paper
• Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge.

  1972cited by this paper
• Lecithin: cholesterol acyltransferase: effects of substrate composition upon enzyme activity.

  1972cited by this paper
• Formation of

  year unknowncited by this paper

• Lipid‐Lowering Effect and Safety of Ezetimibe and Atorvastatin 5 mg in Patients With Primary Hypercholesterolemia or Mixed Dyslipidemia: A Randomized, Double‐Blind, Parallel, Multicenter, Phase 3 Clinical Trial

  2025cites this paper
• The impact of tamoxifen on apolipoproteins and lipoprotein(a) levels: an updated meta-analysis of randomized controlled trials

  2025cites this paper
• The effect of tamoxifen as an adjuvant therapy for breast cancer on apolipoproteins and lipoprotein(a) concentrations in women: A meta-analysis of randomized controlled trials.

  2024cites this paper
• Profile of Discordant Couples for Human Immunodeficiency Virus Infection Followed in Kinshasa: Case of Monkole Medical Center

  2023cites this paper
• Elevated ApoB/apoA-1 is Associated with in-Hospital Mortality in Elderly Patients with Acute Myocardial Infarction

  2023cites this paper
• The Significance of Apolipoprotein-A in the Long-Term Death of Patients with STEMI

  2022cites this paper
• Novel Biomarkers in Risk Assessment and Management of Hyperlipidemia in Cardiovascular Disease

  2022cites this paper
• Muscle invasive bladder cancer and radical cystectomy: a risk predictive model

  2022cites this paper
• Role of Apolipoproteins B and A1 in the Development of Arterial Hypertension against the Background of Obesity

  2020cites this paper
• Comparison of the Efficacy and Safety of Rosuvastatin/Ezetimibe Combination Therapy and Rosuvastatin Monotherapy on Lipoprotein in Patients With Type 2 Diabetes: Multicenter Randomized Controlled Study

  2020cites this paper
• Pregnancy in metabolic healthy and unhealthy obese women

  2020cites this paper
• Is the Preoperative Glycated Hemoglobin (HbA1c) Level Predictive of the Severity of Diabetic Hand Infection According to Surgical and Clinical Outcomes?

  2019cites this paper
• A 3-SNP gene risk score and a metabolic risk score both predict hypertriglyceridemia and cardiovascular disease risk.

  2019cites this paper
• Novel Biomarkers in Risk Assessment and Management of Cardiovascular Disease

  2019cites this paper
• Utility of apolipoprotein measurements in predicting incident type 2 diabetes: A Chinese cohort study.

  2019cites this paper
• Novel Biomarkers in Risk Assessment and Management of Cardiovascular Disease Policy Number : 2 . 04 . 65 Last Review : 1 / 2019 Origination : 1 / 2011 Next

  2018cites this paper
• Title : Novel Biomarkers in Risk Assessment and Management of Cardiovascular Disease Professional Institutional

  2018cites this paper
• Associations Between Dietary Antioxidant Intake and Markers of Atherosclerosis in Middle–Aged Women From North-Western Algeria

  2018cites this paper
• ApoB/ApoA‐I Ratio is Associated With Faster Hemodynamic Progression of Aortic Stenosis: Results From the PROGRESSA (Metabolic Determinants of the Progression of Aortic Stenosis) Study

  2018cites this paper
• Novel Biomarkers in Risk Assessment and Management of Cardiovascular Disease

  2018cites this paper
• Apolipoprotein B/apolipoprotein A1 ratio and mortality among incident peritoneal dialysis patients

  2018cites this paper
• Novel Biomarkers in Risk Assessment and Management of Cardiovascular Disease Policy Number : 2 . 04 . 65 Last Review : 1 / 2018 Origination : 1 / 2011 Next

  2018cites this paper
• Update on the laboratory investigation of dyslipidemias.

  2018cites this paper
• Efficacy and tolerability of two different formulations of atorvastatin in Korean patients with hypercholesterolemia: a multicenter, prospective, randomized clinical trial

  2017cites this paper
• Novel Biomarkers in Risk Assessment and Management of Cardiovascular Disease Description

  2017cites this paper
• Apolipoprotein C-III Levels and Incident Coronary Artery Disease Risk: The EPIC-Norfolk Prospective Population Study

  2017cites this paper
• Apolipoproteins A-I, B, and C-III and Obesity in Young Adult Cherokee

  2017cites this paper
• APO B/APO AI Ratio with Coronary Artery Disease with Normal Lipid Profile in the Indian Population.

  2017cites this paper
• Effects of the DASH-JUMP dietary intervention in Japanese participants with high-normal blood pressure and stage 1 hypertension: an open-label single-arm trial

  2016cites this paper
• Lipids and apolipoproteins in cardiovascular disease

  2016cites this paper
• Novel Biomarkers in Risk Assessment and Management of Cardiovascular Disease

  2016cites this paper
• Factors influencing atherogenic indices in type 2 diabetic women in northwestern Algeria

  2016cites this paper
• Title : Novel Biomarkers in Risk Assessment and Management of Cardiovascular Disease Professional Institutional

  2016cites this paper
• Lipoprotein Biomarkers and Risk of Cardiovascular Disease: A Laboratory Medicine Best Practices (LMBP) Systematic Review.

  2016cites this paper
• Impact of corpulence parameters and haemoglobin A1c on metabolic control in type 2 diabetic patients: comparison of apolipoprotein B/A-I ratio with fasting and postprandial conventional lipid ratios

  2015cites this paper
• Dissecting lipid and lipoprotein issues in women: an in utero-through-menopause journey

  2015cites this paper
• Lipoproteins and Cardiovascular Disease Risk

  2015cites this paper
• The value of apoA-I in predicting heart disease and myocardial infarction

  2015cites this paper
• Substitution of whole cows’ milk with defatted milk for 4 months reduced serum total cholesterol, HDL-cholesterol and total apoB in a sample of Mexican school-age children (6–16 years of age)

  2015cites this paper
• The Apolipoprotein B/Apolipoprotein A-I Ratio as a Potential Marker of Plasma Atherogenicity

  2015cites this paper
• Is Apolipoprotein B and Small, Dense low density lipoprotein a better marker of cardiovascular risk?

  2015cites this paper
• Do apolipoproteins improve coronary risk prediction in subjects with metabolic syndrome? Insights from the North Italian Brianza cohort study.

  2014cites this paper
• Apolipoprotein B and apolipopotein A-I in vascular risk prediction - a review.

  2014cites this paper
• Association of the Apolipoprotein B/Apolipoprotein A-I Ratio, Metabolic Syndrome Components, Total Cholesterol, and Low-Density Lipoprotein Cholesterol with Insulin Resistance in the Population of Georgia

  2014cites this paper
• Apolipoprotein B/Apolipoprotein A-I Ratio and Apolipoprotein B

  2014cites this paper
• Apolipoprotein B attenuates albuminuria-associated cardiovascular disease in prevention of renal and vascular endstage disease (PREVEND) participants.

  2014cites this paper
• Apolipoproteins do not add prognostic information beyond lipoprotein cholesterol measures among individuals with obesity and insulin resistance syndromes: the ARIC study

  2014cites this paper
• Extended-release niacin/laropiprant improves endothelial function in patients after myocardial infarction

  2014cites this paper
• Apolipoproteins: Good Markers for Cardiovacular Risk in Patients with Chronic Kidney Disease and Dyslipidemia

  2014cites this paper
• Common variation in cholesteryl ester transfer protein: relationship of first major adverse cardiovascular events with the apolipoprotein B/apolipoprotein A-I ratio and the total cholesterol/high-density lipoprotein cholesterol ratio.

  2013cites this paper
• Effects of Ezetimibe/Simvastatin 10/20 mg vs. Atorvastatin 20 mg on Apolipoprotein B/Apolipoprotein A1 in Korean Patients with Type 2 Diabetes Mellitus: Results of a Randomized Controlled Trial

  2013cites this paper
• Evaluation of dyslipidaemia in patients with rheumatoid arthritis in South Indian population

  2013cites this paper
• ABCA1 mutation carriers with low high-density lipoprotein cholesterol are characterized by a larger atherosclerotic burden.

  2013cites this paper
• The ApoB/A-I Ratio and Metabolic Syndrome in Prepubertal Children

  2013cites this paper
• Tamoxifen Therapy in Breast Cancer: Do Apolipoprotein E Genotype and Menopausal State Affect Plasma Lipid Changes Induced by the Drug?

  2013cites this paper
• Non‐HDL cholesterol vs. Apo B for risk of coronary heart disease in healthy individuals: the EPIC‐Norfolk prospective population study

  2013cites this paper
• The Methodology of Human Diseases Risk Prediction Tools

  2013influential citation
• Lipoprotein and Lipid Metabolism

  2013cites this paper
• Risk factors for hypertension in a population-based sample of postmenopausal women in Kolkata, West Bengal, India

  2013cites this paper
• Laboratory Diagnostics of Dyslipidemia : From Cholesterol to Apolipoproteins

  2013cites this paper
• UvA-DARE ( Digital Academic Repository ) HDL cholesterol : atherosclerosis and beyond

  2013cites this paper
• The apoB/apoA-I Ratio is a Strong Predictor of Cardiovascular Risk

  2012cites this paper
• Comparison of Apolipoprotein (apoB/apoA-I) and Lipoprotein (Total Cholesterol/HDL) Ratio Determinants. Focus on Obesity, Diet and Alcohol Intake

  2012cites this paper
• Prediction of Risk Factors for Coronary Heart Disease Using Framingham Risk Score in Korean Men

  2012cites this paper
• The plasma leptin/adiponectin ratio predicts first cardiovascular event in men: a prospective nested case-control study.

  2012cites this paper
• Association of apolipoprotein A1 and B with kidney function and chronic kidney disease in two multiethnic population samples.

  2012cites this paper
• Dyslipidemia is a strong predictor of myocardial infarction in subjects with chronic kidney disease

  2012cites this paper
• Ajuga iva aqueous extract improves reverse cholesterol transport in streptozotocin‐induced diabetic rat

  2012cites this paper
• Risk stratification in cardiovascular disease primary prevention – scoring systems, novel markers, and imaging techniques

  2012cites this paper
• Risk prediction of incident coronary heart disease in the Netherlands: re-estimation and improvement of the SCORE risk function

  2012cites this paper
• Living with chronic kidney disease: related issues and treatment.

  2012cites this paper
• What is the role of advanced lipoprotein analysis in practice?

  2012cites this paper
• Tamoxifen alters the plasma concentration of molecules associated with cardiovascular risk in women with breast cancer undergoing chemotherapy.

  2012cites this paper
• Opening a new lipid "apo-thecary": incorporating apolipoproteins as potential risk factors and treatment targets to reduce cardiovascular risk.

  2011cites this paper
• Modulation of cardiovascular risk factors and inflammation in rheumatic diseases

  2011cites this paper
• [Classic and emergent cardiovascular risk factors in schoolchildren in Asturias].

  2011cites this paper
• Non-HDL cholesterol shows improved accuracy for cardiovascular risk score classification compared to direct or calculated LDL cholesterol in a dyslipidemic population.

  2011cites this paper
• Supplementation of Cheonggukjang and Red Ginseng Cheonggukjang Can Improve Plasma Lipid Profile and Fasting Blood Glucose Concentration in Subjects with Impaired Fasting Glucose

  2011cites this paper
• Biomarkers of Asymptomatic Carotid Stenosis in Patients Undergoing Coronary Artery Bypass Grafting

  2011cites this paper
• On‐treatment lipoprotein components and risk of cerebrovascular events in the Treating to New Targets study

  2011cites this paper
• Dyslipidaemia in Rheumatological Autoimmune Diseases

  2011cites this paper
• Apolipoprotein B/A‐I and total cholesterol/high‐density lipoprotein cholesterol ratios both predict cardiovascular events in the general population independently of nonlipid risk factors, albuminuria and C‐reactive protein

  2011cites this paper
• Lipid parameters for measuring risk of cardiovascular disease

  2011cites this paper
• Apolipoproteins and Diabetic Retinopathy

  2011cites this paper
• Efficacy and Safety of Combination Antiplatelet Therapies in Patients With Symptomatic Intracranial Atherosclerotic Stenosis

  2011cites this paper
• Cardiovascular risk assessment

  2011cites this paper
• Effective Lipid-lowering Therapy in High-risk Patients

  2011cites this paper
• Causal Inference for Case-Control Studies

  2011cites this paper
• LDL-C/HDL-C Ratio Predicts Carotid Intima-Media Thickness Progression Better Than HDL-C or LDL-C Alone

  2011cites this paper
• Usefulness of insulin resistance estimation and the metabolic syndrome in predicting coronary atherosclerosis in type 2 diabetes mellitus.

  2011cites this paper
• Traducciones seleccionadas del Clinical Chemistry

  2011cites this paper
• Adiponectin and risk of coronary heart disease in apparently healthy men and women (from the EPIC-Norfolk Prospective Population Study).

  2011cites this paper
• El Colesterol no-HDL demuestra una mejor exactitud en el score de la clasificación del riesgo cardiovascular comparado con el colesterol LDL, directo o calculado, en una población dislipémica

  2011cites this paper
• Serum palmitic acid-oleic acid ratio and the risk of coronary artery disease: a case-control study.

  2011cites this paper
• Serum Levels of Apolipoprotein A-I and B in Rural Schoolchildren

  2011cites this paper
• Emerging options in the treatment of dyslipidemias: a bright future?

  2011cites this paper
• Ability of traditional lipid ratios and apolipoprotein ratios to predict cardiovascular risk in people with type 2 diabetes

  2010cites this paper
• Predictors of the intima‐media thickness of carotid artery in asymptomatic newly detected severe hypercholesterolemic patients

  2010cites this paper
• Exercise training ameliorates the effects of rosiglitazone on traditional and novel cardiovascular risk factors in patients with type 2 diabetes mellitus.

  2010cites this paper
• Das Metabolische Syndrom bei Frauen mit koronarer Herzkrankheit

  2010cites this paper